

NCIC CLINICAL TRIALS GROUP

LEUKEMIA

AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 28, 2007 - 8:30 a.m. - 11:30 a.m.
Room: Seymour

Chair: Dr. Stephen Couban

*Meeting is open to all members of the Hematology Disease Site Group. It is not open to industry representatives. Please note that the Myeloma Committee will be meeting concurrently. The meeting must end at 11:30 a.m because of subsequent meetings including the Hematology Young Investigators meeting, Hematology Correlative Science Committee meeting and the Disease Site Chairs meeting.

8:30 a.m. **INTRODUCTION AND BRIEF OVERVIEW OF CURRENT TRIALS** S. Couban

Focus of group: strengths and challenges
Active Trials: AL.4, ALC.1, CM.1, CLC.1, CLC.2

CORRELATIVE SCIENCE

9:00 a.m. Correlative Proposal for CLC.1 M. Seftel / S. Gibson
Other Correlative Proposals All

NEW STUDY PROPOSALS

9:15 a.m. AML Sorafenib Study B. Leber / D. MacDonald
9:25 a.m. PMH Proposal J. Brandwein
9:45 a.m. Dasatinib / FTI B. Leber / S. Couban
9:55 a.m. Ribvarin Proposal D. Roy
10:05 a.m. Relapsed CLL Proposal M. Seftel / J. Johnston

10:15 a.m. **BREAK**

NEW STUDY PROPOSALS - CONTINUED

10:30 a.m. RICT for CLL M. Seftel
10:40 a.m. Other New Proposals, Including NA Intergroup Update
11:00 a.m. New Farber ALL Proposal D. De Angelo